Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Andrii I. Rozhok
Urea Cycle Sustains Cellular Energetics Upon EGFR Inhibition in EGFR Mutant NSCLC
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
Related publications
EGFR Inhibition in NSCLC: New Findings…. And Opened Questions?
Critical Reviews in Oncology/Hematology
Gerontology
Geriatrics
Hematology
Oncology
Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Expert Review of Anticancer Therapy
Oncology
Pharmacology
Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases
Scientific Reports
Multidisciplinary
P3.13-23 EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Inhibition of Hsp90 Down-Regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
Cancer Research
Cancer Research
Oncology
P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients With Brain Metastases From EGFR-Mutant NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression
Molecular Cancer Therapeutics
Cancer Research
Oncology
